ReviewFrontiers in pediatrics2026
Insights Into monoclonal antibodies and vaccines targeting respiratory viruses.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Viral respiratory infections are a leading cause of morbidity and mortality in children worldwide, with lower respiratory tract infections (LRTIs) a major contributor to hospitalizations and healthcare utilization. Among respiratory pathogens, respiratory syncytial virus (RSV) is the leading cause of severe disease in early life and has driven major advances in preventive strategies. Increasing evidence also suggests that early-life viral infections may influence long-term respiratory outcomes, including recurrent wheezing and asthma. Aim of the study: This article provides a comprehensive overview of the epidemiological burden, risk factors, and long-term consequences of pediatric viral infections. It also examines RSV as a case study in the evolution of preventive strategies and explores knowledge that can be translated from RSV management to other major respiratory viruses, including influenza, SARS-CoV-2, rhinovirus, human metapneumovirus (HMPV), and parainfluenza. Discussion: RSV has reshaped pediatric respiratory prevention through the development of monoclonal antibodies and maternal vaccination strategies, enabling a shift from high-risk-based approaches to broader population-level protection. Advances in structural virology have enabled targeting of conserved viral epitopes, thereby improving efficacy and the duration of protection. Similar strategies are being explored for other respiratory viruses. However, antigenic variability, limited pediatric data, and incomplete vaccine effectiveness remain significant barriers. Conclusion: RSV experience provides a robust foundation for preventing viral respiratory infections. Integrating passive and active immunization strategies, targeting conserved viral structures, and improving global access are essential to reduce the disease burden of pediatric respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.